The following drugs are mentioned in the video roundtable discussion. Information on these drugs provided below is accurate as of March 26, 2010.
Colesevelam (Welchol; Daiichi Sankyo, Inc., Parsippany, New Jersey) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, in addition to an indication for reducing elevated low-density lipoprotein cholesterol in adults and children 10-17 years of age. It is approved for the treatment of type 2 diabetes in the United States.
Exenatide (Byetta; Amylin Pharmaceuticals Inc., San Diego, California/Eli Lilly and Company, Indianapolis, Indiana) is indicated in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide is indicated in the European Union for treatment of type 2 diabetes mellitus in combination with metformin and/or sulfonylureas in patients who have not achieved adequate glycemic control on maximally tolerated doses of these oral therapies. It is approved in Argentina, Australia, Chile, China, Colombia, the European Union, Iceland, India, Israel, New Zealand, Norway, Russia, South Korea, Switzerland, and the United States. It is under review in Canada and Japan.
Liraglutide (Victoza; Novo Nordisk A/S, Bagsvaerd, Denmark) is indicated in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In the European Union, liraglutide is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycemic control in combination with metformin or a sulfonylurea in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin or sulfonylurea or in combination with metformin and a sulfonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy. It is approved in the European Union, Japan, and the United States. It is under review in Argentina, Australia, Brazil, Canada, Mexico, New Zealand, Norway, Russia, South Africa, Switzerland, and Turkey.
Rosiglitazone (Avandia; GlaxoSmithKline, Research Triangle Park, North Carolina) is indicated as monotherapy or combination therapy as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is approved in Argentina, Australia, Brazil, Canada, China, Colombia, Costa Rica, the European Union, Guatemala, Hong Kong, India, Israel, Japan, Kenya, Malaysia, Mexico, New Zealand, Norway, Pakistan, Panama, the Philippines, Saudi Arabia, Singapore, South Korea, Switzerland, Thailand, Turkey, and the United States.
Saxagliptin (Onglyza; Bristol-Myers Squibb Company, Princeton, New Jersey/AstraZeneca Pharmaceuticals LP, Indianapolis, Indiana) is indicated in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In the European Union, saxagliptin is indicated as add-on combination therapy in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycemic control; in combination with a sulfonylurea, when the sulfonylurea alone, with diet and exercise, does not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate; in combination with a thiazolidinedione (TZD), when the TZD alone with diet and exercise does not provide adequate glycemic control in patients for whom use of a TZD is considered appropriate. It is approved in the European Union, Japan, Mexico, and the United States.
Sitagliptin (Januvia; Merck & Co., Inc, Whitehouse Station, New Jersey) is indicated in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In the European Union, sitagliptin is indicated for patients with type 2 diabetes mellitus to improve glycemic control as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance; as dual oral therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycemic control, in combination with a sulfonylurea when diet and exercise plus maximal tolerated dose of a sulfonylurea alone do not provide adequate glycemic control and when metformin is inappropriate due to contraindications or intolerance; a thiazolidinedione (TZD) when use of a TZD is appropriate and when diet and exercise plus the TZD alone do not provide adequate glycemic control; or as triple oral therapy in combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycemic control, a TZD and metformin when use of a TZD is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycemic control. Sitagliptin is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycemic control. It is approved in Australia, Barbados, the Bahamas, Brazil, the Cayman Islands, Canada, the European Union, Iceland, India, Japan, Mexico, Norway, Peru, the Philippines, South Korea, Switzerland, and the United States.
Vildagliptin (Galvus; Novartis Europharma Limited, West Sussex, England) Vildagliptin is indicated in the treatment of type 2 diabetes mellitus as dual oral therapy in combination with metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin, in combination with a sulfonylurea in patients with insufficient glycemic control despite maximal tolerated dose of a sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance, or in combination with a thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate. It is approved in Brazil, the European Union, Iceland, India, Japan, Mexico, Norway, South Korea, and Switzerland.